Trial Profile
A 12-week, Open Label, Multicenter, Titration Study, With a 12 Month Extension, to Determine the Optimal Titration Regimen for SBR759, Compared to Sevelamer HCl, in Lowering Serum Phosphate Levels in Asian Patients With Chronic Kidney Disease on Haemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SBR 759 (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 Sep 2014 New trial record
- 20 Jul 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.